Medtronic is expected to report Q1 earnings of $1.39 per share, up 10.3% year-over-year, with revenues projected at $9.47 billion, representing 10.4% growth. Analysts forecast broad-based growth across most business segments, including Cardiovascular (+15.2%), Diabetes (+15.1%), and Neuroscience (+10.7%). The stock has outperformed the S&P 500 with +5.1% returns over the past month and carries a Zacks Rank #3 (Hold) rating.

The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.

The global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.

The global Intravascular Lithotripsy (IVL) market is projected to grow from USD 1.01 billion in 2025 to USD 4.19 billion by 2035, expanding at a 15.3% CAGR. Growth is driven by increasing prevalence of calcified coronary and peripheral artery disease, adoption of minimally invasive procedures, and expanding peripheral IVL applications. North America leads with 58% market share, while Asia-Pacific is the fastest-growing region.

Intuitive Surgical faces new competition from Medtronic and Johnson & Johnson in the surgical robotics space, but maintains a strong market position with 11,710 da Vinci systems in use globally. The company's real strength lies in its recurring revenue from instruments, accessories, and services (75% of revenue), rather than system sales alone. Despite a 40% stock decline and a 42x P/E ratio, the company's large installed base and annuity-like income streams provide a competitive moat that positions it favorably for growth-oriented investors.

Medtronic's stock has declined over 30% in the past five years due to cost pressures and competitive challenges, but analyst Leo Sun believes it could rise 40% to $121 by end of 2026. The company's recent diabetes unit spinoff, business restructuring focused on higher-margin cardiovascular and neuroscience portfolios, and strong revenue growth (8.4% in fiscal 2026) position it for recovery. Trading at 18x forward earnings with a 3.3% dividend yield and potential Dividend King status next year, Medtronic could attract significant investor attention.

Ceribell announced the appointment of Thomas West and Sharon O'Keefe to its Board of Directors. West, former CEO of Nalu Medical (acquired by Boston Scientific for $600M) and Intersect ENT (acquired by Medtronic for $1.1B), and O'Keefe, former President of University of Chicago Medical Center, bring significant commercial and health-system leadership experience. The appointments support Ceribell's expansion as its point-of-care brain monitoring platform is now deployed in over 680 U.S. hospitals.

Implicity announced FDA 510(k) clearance for its next-generation ILR ECG Analyzer, a cloud-based AI software that reduces false-positive alerts from implantable cardiac monitors by up to 76% while maintaining high sensitivity. The manufacturer-agnostic algorithm works with devices from Abbott, Biotronik, Boston Scientific, and Medtronic, addressing a significant clinical workflow burden in remote cardiac monitoring.

The global ultrasonic aspirator market is valued at USD 194.03 million in 2025 and is projected to reach USD 376.32 million by 2035, growing at a CAGR of 6.87%. The U.S. market is expected to grow from USD 67.49 million to USD 118.90 million by 2035, driven by increasing adoption of advanced surgical technologies, rising neurosurgery procedures, and growing demand for minimally invasive surgeries. North America leads the market with 39.80% share, while Asia-Pacific registers the fastest growth at 8.83% CAGR.

The global electrosurgery market is projected to grow from $8.01 billion in 2025 to $11.59 billion by 2031, with a CAGR of 6.4%. Growth is driven by increasing surgical volumes, rising chronic disease prevalence, and adoption of minimally invasive procedures. However, challenges include procedural risks, regulatory constraints, and surgeon shortages. Ambulatory surgical centers are expanding their role, while the United States leads North American growth.

The global implantable cardiac fluorine-free resins market is valued at USD 1.52 billion in 2025 and is expected to grow to USD 4.26 billion by 2035 at a CAGR of 10.8%. Growth is driven by increasing cardiovascular disease prevalence, aging demographics, demand for biocompatible materials, and advancements in manufacturing technologies like additive manufacturing. Asia Pacific is projected to experience the fastest growth, while North America and Europe maintain steady expansion.

The global robotic endoscopy devices market is projected to grow from USD 2.8 billion in 2025 to USD 6.5 billion by 2034, driven by increasing demand for minimally invasive procedures, technological advancements in AI-enabled navigation and imaging, and rising prevalence of gastrointestinal disorders. North America leads the market with 42% share, while Asia-Pacific is expected to witness the highest growth. Key players include Intuitive Surgical, Medtronic, Johnson & Johnson MedTech, and others.